• Event Type: Q1 FY27 Earnings Conference Call to discuss unaudited financial results for quarter ended June 30, 2026.
  • Date and Time: The call was held on August 07, 2026. Specific time and time zone were not mentioned in the transcript.
  • Purpose: Discussion of quarterly results, strategic update, and operational performance. The meeting was held after earnings announcement.
  • Management Participants: Dr. Manish Mattoo (Executive Director and CEO), Mr. Sanjeev Kumar (Chief Financial Officer), and Mr. Ravi Gothwal (Head of Investor Relations).
  • Presentation Availability: The earnings presentation was shared with participants earlier and is available on the company website at https://www.hcgoncology.com/investor-relations/.
  • UPSI Statement: The company included a standard disclaimer that some statements made during the discussion may be forward-looking in nature.

Financial Highlights Discussed:

  • Quarter Discussed: Q1 FY27 (quarter ended June 30, 2026)
  • Revenue Performance: INR6,951 million, representing 13% year-on-year growth
  • Growth Drivers: 11% increase in patient volumes, 2% growth in Average Revenue Per Patient (ARPP)
  • Segment Performance:
  • South cluster: ~16% growth (includes new North Bangalore hospital contribution of INR67 million)
  • West cluster: 9% growth
  • East cluster: 22% growth
  • Profitability Metrics:
  • Reported EBITDA: INR1,223 million
  • Adjusted EBITDA (excluding North Bangalore losses and one-off costs): INR1,339 million, up 20% YoY
  • EBITDA margins: 19.4% vs 18.2% in Q1 FY26
  • Strategic Developments:
  • Successful divestment of Fertility business completed at end of June 2026
  • Successful rights issue strengthened balance sheet (INR170 crore used for debt repayment)
  • North Bangalore hospital commenced operations in May 2026
  • Added 121 operational beds across network in Q1
  • Forward-looking Statements:
  • Long-term EBITDA margin target of 24-25%
  • Bed expansion plan: 65 beds in FY27, 520 beds in FY28-FY29, 230 beds in FY30
  • 60% of capacity expansion through brownfield projects
  • 3 greenfield projects in pipeline

Additional Notes Section

  • The document is a transcript of the earnings call with analysts/investors, filed as a regulatory disclosure under SEBI LODR Regulations.
  • The transcript contains detailed management commentary on financial performance, operational metrics, strategic initiatives, and expansion plans.
  • Financial data was extensively disclosed including revenue figures, EBITDA metrics, growth rates, and capital expenditure details.
  • The company indicated that the North Bangalore hospital reached peak EBITDA loss in Q1 and expects losses to reduce in subsequent quarters.
  • The impact of discontinuation of some chemo drugs was quantified as 1.5% on top line but margin-accretive.